Hope bearer in oncology: Genmab impresses with Phase 2 data on Petosemtamab

Strong response rates: In combination with standard chemotherapy, Petosemtamab achieves response rates of 75 percent in the first line and 67 percent in the second line for metastatic colorectal cancer. Solid safety profile: Low treatment-related dropout rates of 3 to 5 percent and no treatment-related deaths indicate good tolerability. Strategic pipeline validation: The matured data support the global Phase 3 study program and underscore the commercial potential of the bispecific antibody. At the annual congress of the European...